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Introduction
Interleukin 2 (IL-2) is a lymphocytotrophic cytokine that is
involved in the growth and differentiation of T and B cells
and enhances the cytolytic functions of natural killer (NK)
cells; it is also known to have some function in the prolifer-
ation of several non-lymphoid cells [1,2]. IL-2 receptor
complex (IL-2R) comprises three subunits (α,  β and  γ),
encoded by unrelated genes [3]. The affinity of IL-2R
depends on which subunits are expressed at the cell
surface [4,5]: β and γ chains together form the intermedi-
ate-affinity receptor, whereas the high-affinity receptor
requires the additional presence of the α subunit [6].
IL-2 has been detected in normal tissues including the
endothelium, the intestinal epithelium and nerve cells [7].
Increased expression of IL-2 and IL-2R has been reported
in actively proliferating tumours such as stomach, renal
and spinocellular cancers [8], squamous cell carcinomas
of the head and neck [9], melanomas, neuroblastic
tumours [10] and prostate cancer [11].
IL = interleukin; IL-2R = interleukin-2 receptor; TBS = Tris-buffered saline.
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Abstract
Introduction. The presence and distribution of interleukin-2
(IL-2) and its receptor complex (Rα, Rβ, Rγ) were studied in
52 women who were clinically and histopathologically
diagnosed with breast tumours (17 in situ and 35
infiltrating), and in 13 women with benign fibrocystic lesions
in the breast.
Methods. Immunohistochemistry with antibodies against IL-2,
IL-2Rα, IL-2Rβ and IL-2Rγ was used. A comparative
semiquantitative immunohistochemical study between the three
breast groups (fibrocystic lesions, in situ tumours and
infiltrating tumours) was performed.
Results. IL-2 and its three receptor chains were
immunodetected in the cytoplasm of epithelial cells. The three
receptor chains were also detected on the cell surface. In
fibrocystic lesions, immunoreactions to IL-2 (38.5% of cases),
IL-2Rα (53.8%) and IL-2Rβ (30.8%) were very weak, whereas
immunoreaction to IL-2Rγ (46.1%) was somewhat more
intense. In in situ tumours, the percentages of cases that
immunostained positively for IL-2 and its three receptor chains
were similar to those observed in fibrocystic lesions, but
immunostainings of the four antibodies were more intense. In
infiltrative tumours, the percentages of positively stained cases
and also immunostaining intensities were approximately twice
that found for in situ tumours. Within infiltrating tumours, the
percentage of cases showing immunoreaction to IL-2 and their
three receptor chains was higher in the patients with lymph
node infiltration at the time of surgery.
Conclusion. The development of breast tumour is associated
with an increased expression of IL-2 and its three receptor
chains, and this expression also seems to be associated with
the malignancy of the tumour.
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In normal tissues [7] and several tumours, including
stomach, renal and spinocellular cancer [8] and squamous
cell carcinomas of the head and neck [9], IL-2 seems to
stimulate cell proliferation and is more abundant in mitotic
cells than in cells in the other phases of the cell cycle [8,9].
Experimental studies of squamous cell carcinomas of head
and neck have shown that antisense IL-2 treatment or
blocking of IL-2Rβ results in growth inhibition [12].
Nevertheless, it has also been shown that systemic admin-
istration of IL-2 induces the regression of metastatic
murine renal carcinoma [13], possibly through the induc-
tion of interferon-γ, tumour necrosis factor-α and anti-
angiogenic products such as IP-10 [14]. This finding has
led to some authors to conclude that whereas endoge-
nous IL-2 stimulates cell proliferation, exogenous IL-2
inhibits such a proliferation [7,15].
Studies on IL-2 and its receptors in breast cancer are few.
Katano and colleagues [16] cultured two breast carci-
noma cell lines (M and M25-SF lines), and found IL-2
expression in the latter line only. In vivo immunohistochem-
ical studies of IL-2Rα and IL-2Rβ in ductal infiltrating
breast cancer by Ridings and colleagues [10] revealed
that only the β receptor chain was present in these
tumours.
The aim of the present study was to characterise the
expression patterns of IL-2 and its three receptor chains
(α, β and γ) by immunohistochemistry, in both in situ and
infiltrating breast tumours, to elucidate the role of these
proteins in breast cancer progression and metastasis.
Materials and methods
Total or partial mastectomy specimens obtained from
52 women, who were clinically and histopathologically
diagnosed with breast adenocarcinoma during 1998 in
our hospital, were used for the study. Seventeen of these
women (aged from 47 to 75 years) presented in situ carci-
noma (8 lobular and 9 ductal); 1 of these 17 women also
showed lymph node infiltration at the time of surgery.
Thirty-five women (aged from 51 to 77 years) had infiltrat-
ing carcinoma (15 lobular and 20 ductal); 13 of these
35 women showed lymph node infiltration at the time of
surgery, and 7 of these 13 developed metastasis
7–24 months after surgery. At present (January 2003),
neither the remaining 22 women with infiltrating tumours
nor the 17 women with in situ tumours have developed
metastasis.
Tumour samples were compared with breast biopsies
from 13 women (aged from 16 to 59 years) with benign
fibrocystic lesions. Removal of tissues and the study of
samples were approved by the Hospital’s Ethics Commit-
tee and were performed with the consent of the patients’
relatives.
All samples were processed for immunohistochemical
study by light microscopy. The primary antibodies used
were goat anti-human IL-2, rabbit anti-human IL-2Rα,
rabbit anti-human IL-2Rβ and rabbit anti-human IL-2Rγ
(Santa Cruz Biotechnology, California, CA, USA).
Tissues were fixed for 24 hours at room temperature in
0.1M phosphate-buffered 10% formaldehyde, then dehy-
drated and embedded in paraffin. Sections (5µm thick)
were processed with the avidin–biotin–peroxidase complex
(ABC) method. Following deparaffination, sections were
hydrated and then incubated for 30 minutes in 0.3% H2O2
diluted in methanol to reduce endogenous activity. After
rinsing in Tris-buffered saline (TBS), the slides were incu-
bated with normal donkey serum at 10% in TBS for
30 minutes, to prevent non-specific binding of the first anti-
body. Thereafter, the primary antibodies were applied at a
dilution of 1:100 for the four antibodies in TBS overnight at
room temperature. The sections were then washed twice in
TBS and incubated with rabbit anti-(goat IL-2), or pig anti-
(rabbit IL-2Rα, IL-2Rβ and IL-2Rγ) biotinylated immunoglob-
ulin (Dako, Barcelona, Spain) at 1:500 in TBS. After
incubation for 1 hour with secondary antibody, the sections
were incubated with a standard streptavidin–biotin complex
(Vector Laboratories, Burlingame, CA, USA) and developed
with 3,3′-diaminobenzidine (DAB), using the glucose
oxidase–DAB–nickel intensification method.
Immunochemical procedure specificity was checked with
negative and positive controls. For negative controls of
immunoreactions, tissues of each type were incubated
with preimmune serum at the same immunoglobulin con-
centration as that used for each antibody, or with blocking
peptides (Santa Cruz Biotechnology). As positive controls,
histological sections (immunohistochemistry) of thymus
samples were incubated with the same antibodies.
A comparative histological quantification of immunola-
belling among the different groups of breast samples (in
situ adenocarcinomas, infiltrating adenocarcinomas and
benign fibrocystic lesions) was performed for each of the
four antibodies. For each breast sample, six histological
sections were selected at random. In each section, the
staining intensity (optical density) per unit surface area
was measured with an automatic image analyser (MIP4
version 4.4; Consulting Image Digital, Barcelona, Spain) in
five light microscopic fields per section, using the 40×
objective. Delimitation of stained surface areas was per-
formed manually with the mouse of the image analyser. For
each positively immunostained section, one negative
control section (the next in a series of consecutive sec-
tions) was also used, and the optical density of this control
section was subtracted from that of the stained section.
From the average values obtained for each breast, the
means±SD for each breast group were calculated. The
statistical significance between means of the differentR3
breast group samples was assessed by the Fisher and
Behrens test at P≤0.05, by multiple pairwise comparisons
of all the values for each breast zone, for each specific
antibody separately.
To test whether the increase in IL-2 immunoexpression
intensity (optical density) was correlated with the increase
in expression of each IL-2 receptor chain, Pearson’s coef-
ficient of correlation was calculated for each of the follow-
ing pair of values (IL-2 and IL-2Rα, IL-2 and IL-2Rβ, IL-2
and IL-2Rγ).
Results
No immunoreaction was observed in the negative controls
incubated with preimmune serum or with the use of the
antibodies preabsorbed with an excess of purified antigen.
Staining of thymus sections (positive controls) was always
positive for all antibodies used (Figs 1a, 2a, 3a and 4a).
In the three groups of specimens (fibrocystic lesions, in
situ tumours and infiltrating tumours), immunostaining of
IL-2 appeared in the cytoplasm of epithelial cells, whereas
immunostaining of the three types of IL-2R (α, β and γ)
appeared in both the cell surface and cytoplasm of epithe-
lial cells.
For each antibody assayed, the percentage of positive
cases and immunostaining intensities are shown in
Table 1. The immunostaining intensities (optical density)
are given as means±SD. Significance was determined by
multiple pairwise comparisons by the Fisher and Behrens
test at P≤0.05. All the values for each breast zone and for
each specific antibody were compared separately.
Immunoreaction to IL-2 was found in 38.5% of benign
fibrocystic lesions (Fig. 1b,c), in 41.2% of in situ tumours
(Fig. 1d) and in 82.9% of infiltrating tumours (Fig. 1e).
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Figure 1
IL-2 immunostaining. (a) Thymus sections were used as a positive
control. Fibrocystic lesions show either no immunoreaction (b) or a
weak immunoreaction limited to a circumscribed supranuclear region
(c). In ductal in situ (d) and ductal infiltrating (e) carcinomas, most of
the cytoplasm was labelled. Original magnification ×375.
Figure 2
Immunostaining of IL-2Rα. (a) Moderate staining of thymus section.
(b) Fibrocystic lesions showing a weak immunoreaction. (c) Lobular in
situ carcinoma showing moderate immunostaining. (d) Lobular infiltrating
carcinoma showing a more intense immunostaining. Original
magnification ×375.Immunostaining was very weak in benign fibrocystic
lesions, and more intense in both tumour types.
Immunoreaction to IL-2Rα was present in 53.8% of fibro-
cystic lesions (Fig. 2b), in 35.3% of in situ tumours
(Fig. 2c) and in 60.0% of infiltrating tumours (Fig. 2d).
Immunostaining was very weak in benign fibrocystic
lesions, more intense in in situ tumours, and even more
intense in infiltrating tumours.
Immunoreaction to IL-2Rβ was observed in 30.8% of
fibrocystic lesions and was very weak (Fig. 3b). An intense
immunoreaction was detected in 35.3% of in situ tumours
(Fig. 3c) and in 80.0% of infiltrating tumours (Fig. 3d).
Immunoreaction to IL-2Rγ appeared in 46.1% of fibrocys-
tic lesions. This was the only IL-2 receptor that showed a
certain degree of staining intensity in fibrocystic lesions
(Fig. 4b). Immunoreaction to this receptor was observed in
41.2% of in situ tumours (Fig. 4c), in which staining was
more intense. The most intense immunoreaction appeared
in 80.0% of infiltrating tumours (Fig. 4d).
Within the group of infiltrating carcinomas with lymph
node infiltration (13 women), 10 of them (76.9%) pre-
sented a positive immunoreaction to IL-2 and its three
receptor chains. In the group without lymph node infiltra-
tion (22 women), only 10 cases (45.5%) presented a posi-
tive immunoreaction to IL-2 and its receptors.
The correlation (r) between the immunoexpression inten-
sity of IL-2 and each receptor chain was as follows:
IL-2/IL-2Rα, 0.88; IL-2/IL-2Rβ, 0.97; IL-2/IL-2Rγ, 0.85.
Discussion
Immunohistochemical studies of IL-2 and IL-2R have been
performed in several normal tissues such as human and
murine fibroblasts [17,18], oral mucosae [9] and epithelial
basal cells of the prostate [11], and it has been suggested
that IL-2 is involved in the control of the equilibrium
between proliferation and apoptosis [11]. In all these
normal tissues the expression of IL-2 and IL-2R was weak.
These data agree with present findings in fibrocystic
lesions of the breast. In these specimens, breast epithelial
cells showed a characteristic staining pattern: a weak
immunoreaction to IL-2, limited to a circumscribed cyto-
plasmic area corresponding to the Golgi zone. These
observations suggest that, in breast tissue, this interleukin
is processed and secreted in the same way as in
haematopoietic cells, in agreement with the report by
Sander and colleagues [19].
The functional location of IL-2 receptor complex is the
plasma membrane. Each of the three chains has a cyto-
plasmic domain [20], which binds to intracellular signalling
molecules and thereby relays specific intracellular signals
[21]. In the present study, the three IL-2R chains were
immunodetected not only at the cell surface but also in the
cytoplasm. This intracellular immunoreaction might corre-
spond to neosynthesised receptor chains that have not yet
reached the cell membrane.
During the past decade, consistent results have demon-
strated the occurrence and functional implication of IL-2 in
tumour cells [7,9]. In the present study, in contrast with
the weak immunolabelling observed in benign fibrocystic
lesions, breast tumour cells (in situ tumours, and even
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Table 1
Comparison of immunostaining intensities between groups of breast samples
IL-2 IL-2Rα Il-2Rβ IL-2Rγ
Group Positive Optical Positive Optical Positive Optical Positive Optical
(no. of cases) samples density samples density samples density samples density
Human thymus (4) 4 (100%) 12.1±1.2 4 (100%) 10.07±1.47 4 (100%) 14.33±2.1 4 (100%) 13.21±0.89
Fibrocystic benign 5 (38.5%) 4.02±0.37a 7 (53.8%) 7.13±0.19a 4 (30.8%) 2.05±0.35a 6 (46.1%) 15.40±2.4a
lesions (13)
In situ carcinomas 7 (41.2%) 20.47±2.42b 6 (35.3%) 20.30±1.29b 6 (35.3%) 28.90±1.15b 7 (41.2%) 25.05±2.5b
(17)
Infiltrating carcinomas 29 (82.9%) 26.93±4.82c 21 (60.0%) 52.92±4.77c 28 (80.0%) 31.22±6.80b 28 (80.0%) 40.82±5.78c
(35)
Lymph node infiltration 11 (84.6%) 28.24±4.9c 11 (84.6%) 54.41±4.8c 10 (76.9%) 28.94±5.66b 12 (92.3%) 38. 8±6.12c
(13)
Neither lymph node 18 (81.8%) 26.06±4.89c 10 (45.4%) 51.55±4.79c 18 (81.8%) 32.28±6.80b 16 (72.7%) 42.16±6.93c
infiltration nor metastasis (22)
Optical densities are means±SD. Values denoted by different superscripts are significantly different from each other. Those values sharing the
same superscript are not statistically different from each other. Statistical analysis refers to each antibody separately. Significance was determined
by multiple comparisons by the Fisher and Behrens test at P ≤ 0.05.more in infiltrating tumours) showed a large part of the
cytoplasm immunostained (from moderately to intensely)
to IL-2 and its receptor. According to the staining distribu-
tion there are no specific subpopulations within individual
patients, because IL-2/IL-2R expression was uniform
throughout the whole epithelium. This suggests that IL-2
secretion acts throughout an autocrine mechanism. There
also was a positive correlation between the increased
expression of IL-2 and that of its three receptor chains:
IL-2Rα (r=0.88), IL-2Rβ (r=0.97) and IL-2Rγ (r=0.85).
Nevertheless, more than half of in situ carcinoma patients,
and about 20% of patients with infiltrating carcinomas, did
not immunoreact to IL-2 and IL-2R. The association
between IL-2 and breast cancer might therefore not be
generalised.
The effect of this high expression of IL-2 and IL-2R in
breast cancer cells might be a contribution to the develop-
ment of a tumour by enhancing cell proliferation and/or
inhibiting apoptosis, together with other factors including
anti-apoptotic factors of the Bcl-2 family gene products,
as has been reported in other tumour tissues [11]. Lelle
[22] reported an increase in the proliferation index from
breast benign lesion to tumour tissue. Reicher and col-
leagues [9] described, in tumour cell lines of squamous
cell carcinomas of the head and neck, that tumour cells in
G0, G1 and S phases showed a juxtanuclear localisation of
IL-2, whereas tumour cells in G2 and mitosis showed an
increased IL-2 expression, distributed throughout the
whole cytoplasm [15]. Azzarone and colleagues [7]
reported similar findings in several breast cancer cell lines,
as did Reicher and colleagues [15] in squamous cell car-
cinomas of head and neck.
The expression of IL-2 and its receptors was higher in
breast infiltrating tumours than in in situ tumour samples.
This agrees with the above-mentioned role of IL-2 in
tumour cell proliferation because infiltrating tumours are
more aggressive than in situ tumours. In these latter,
tissue keeps its glandular structure, whereas infiltrating
tumour epithelial cells lose their normal structure and
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Figure 3
Immunostaining of IL-2Rβ. (a) Thymus sections were always positive.
(b) Fibrocystic lesions showing a weak immunoreaction. Ductal in situ
carcinoma (c) and ductal infiltrating carcinoma (d) showing intense
immunostaining. Original magnification ×375.
Figure 4
Immunostaining of IL-2Rγ. (a) Presence of positive immunoreaction in
thymus sections. (b) Fibrocystic lesions showing moderate
immunoreaction. (c) Lobular in situ carcinoma in which immunostaining
was more intense. (d) Even more intense immunostaining in lobular
infiltrating carcinoma than in in situ carcinoma. Original magnification
×375.invade the adjacent stromal tissue [23]. In this context,
Querzoli and colleagues [24] reported that infiltrating
breast cancers have a higher proliferation index than in
situ tumours.
Using immunofluorescence, Ridings and colleagues [10]
found that most infiltrating ductal breast carcinomas were
positive for IL-2Rβ, but only 10% were positive for IL-2Rα.
In contrast, the present study of infiltrating ductal breast
carcinomas revealed an intense expression of β and  γ
chains in 80% of cases, and of α chains in 60% of cases.
Because IL-2Rβ and IL-2Rγ are necessary to form the
active receptor [25], these results suggest that infiltrating
breast tumours expressed functional receptors, able to
respond to IL-2 stimuli.
The increased expression of the γ chain is not exclusively
related to the response to IL-2 stimuli. Because this chain
is also a component of receptor complexes for other inter-
leukins, including IL-4, IL-7 and IL-9 [26,27], the function
of these interleukins might also be enhanced. Several
authors have demonstrated the overexpression of recep-
tors for these interleukins in such different tumours as
lung, renal, melanoma, colorectal and breast [28,29].
Several interleukins, including IL-2, IL-4, IL-5 and IL-10,
have been shown to induce IL-2Rα expression in inflam-
matory processes and viral infections [21]. Because this
chain is necessary to form the high-affinity IL-2R [30],
which enhances the IL-2 signal, the increased expression
of IL-2Rα in breast-infiltrating tumours suggests that the
IL-2 signal is more active in this tumour group.
Conclusion
Although immunohistochemical studies cannot provide
any information about the function of these molecules, the
present data suggest that the development of breast
tumour is associated with an increased expression of IL-2
and its three receptor chains, and this expression also
seems to be associated with the malignancy of the
tumour.
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